Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study

BACKGROUND: The 12-month (M) PROTECT study showed that de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)-based immunosuppression to a CNI-free everolimus (EVR)-based regimen showed numerically better renal function. Here, we present the five-yr follow-up data...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sterneck, Martina (VerfasserIn) , Schemmer, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016 May 10
In: Clinical transplantation
Year: 2016, Jahrgang: 30, Heft: 6, Pages: 741-748
ISSN:1399-0012
DOI:10.1111/ctr.12744
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1111/ctr.12744
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.12744
Volltext
Verfasserangaben:Martina Sterneck, Gernot M. Kaiser, Nils Heyne, Nicolas Richter, Falk Rauchfuss, Andreas Pascher, Peter Schemmer, Lutz Fischer, Christian G. Klein, Silvio Nadalin, Frank Lehner, Utz Settmacher, Daniel Gotthardt, Martin Loss, Stephan Ladenburger, Peter Wimmer, Markus Dworak and Hans J. Schlitt

MARC

LEADER 00000caa a2200000 c 4500
001 1588287742
003 DE-627
005 20220815115047.0
007 cr uuu---uuuuu
008 190304s2016 xx |||||o 00| ||eng c
024 7 |a 10.1111/ctr.12744  |2 doi 
035 |a (DE-627)1588287742 
035 |a (DE-576)518287742 
035 |a (DE-599)BSZ518287742 
035 |a (OCoLC)1341040852 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sterneck, Martina  |e VerfasserIn  |0 (DE-588)1027344100  |0 (DE-627)72897813X  |0 (DE-576)16633782X  |4 aut 
245 1 0 |a Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study  |c Martina Sterneck, Gernot M. Kaiser, Nils Heyne, Nicolas Richter, Falk Rauchfuss, Andreas Pascher, Peter Schemmer, Lutz Fischer, Christian G. Klein, Silvio Nadalin, Frank Lehner, Utz Settmacher, Daniel Gotthardt, Martin Loss, Stephan Ladenburger, Peter Wimmer, Markus Dworak and Hans J. Schlitt 
264 1 |c 2016 May 10 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.03.2019 
520 |a BACKGROUND: The 12-month (M) PROTECT study showed that de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)-based immunosuppression to a CNI-free everolimus (EVR)-based regimen showed numerically better renal function. Here, we present the five-yr follow-up data. METHODS: PROTECT was a randomized controlled study in which LTxR received basiliximab and CNI-based immunosuppression ± corticosteroids. Patients were randomized 1:1 to receive EVR or continue CNI. Patients completing the core study could enter the extension study on their randomized treatment. RESULTS: A total of 81 patients entered the extension study (41, EVR; 40, CNI). At M59 post-randomization, the adjusted mean eGFR was significantly higher in the EVR group, with a benefit of 12.4 mL/min using Cockcroft-Gault (95% CI: 1.2; 23.6; p = 0.0301). Also, there was a significant benefit for adjusted and unadjusted eGFR using the four-variable Modification of Diet in Renal Disease (MDRD4) or Nankivell formula. During the extension period, treatment failure rates were similar. SAEs occurred in 26 (63.4%) and 28 (70.0%) of the patients in EVR and CNI groups, respectively. CONCLUSION: Compared with the CNI-based treatment, EVR-based CNI-free immunosuppression resulted in significantly better renal function and comparable patient and graft outcomes after five-yr follow-up. 
650 4 |a Adult 
650 4 |a calcineurin inhibitors 
650 4 |a Calcineurin Inhibitors 
650 4 |a everolimus 
650 4 |a Everolimus 
650 4 |a Female 
650 4 |a Follow-Up Studies 
650 4 |a Graft Rejection 
650 4 |a Graft Survival 
650 4 |a Humans 
650 4 |a Immunosuppressive Agents 
650 4 |a Kidney Function Tests 
650 4 |a Liver Diseases 
650 4 |a Liver Transplantation 
650 4 |a long-term follow-up 
650 4 |a Male 
650 4 |a Prospective Studies 
650 4 |a renal function 
650 4 |a Treatment Outcome 
650 4 |a Withholding Treatment 
700 1 |a Schemmer, Peter  |d 1967-  |e VerfasserIn  |0 (DE-588)1022604244  |0 (DE-627)717006794  |0 (DE-576)365668230  |4 aut 
773 0 8 |i Enthalten in  |t Clinical transplantation  |d Oxford [u.] : Wiley-Blackwell, 1999  |g 30(2016), 6, Seite 741-748  |h Online-Ressource  |w (DE-627)320439925  |w (DE-600)2004801-4  |w (DE-576)091142652  |x 1399-0012  |7 nnas  |a Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study 
773 1 8 |g volume:30  |g year:2016  |g number:6  |g pages:741-748  |g extent:8  |a Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study 
856 4 0 |u http://dx.doi.org/10.1111/ctr.12744  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.12744  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190304 
993 |a Article 
994 |a 2016 
998 |g 1022604244  |a Schemmer, Peter  |m 1022604244:Schemmer, Peter  |d 910000  |d 910200  |e 910000PS1022604244  |e 910200PS1022604244  |k 0/910000/  |k 1/910000/910200/  |p 7 
999 |a KXP-PPN1588287742  |e 3057159753 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 04.03.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1588287742","language":["eng"],"person":[{"family":"Sterneck","given":"Martina","roleDisplay":"VerfasserIn","display":"Sterneck, Martina","role":"aut"},{"family":"Schemmer","given":"Peter","roleDisplay":"VerfasserIn","display":"Schemmer, Peter","role":"aut"}],"title":[{"title":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study","title_sort":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study"}],"physDesc":[{"extent":"8 S."}],"relHost":[{"language":["eng"],"recId":"320439925","disp":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation studyClinical transplantation","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 13.01.04"],"part":{"volume":"30","text":"30(2016), 6, Seite 741-748","extent":"8","year":"2016","issue":"6","pages":"741-748"},"pubHistory":["Nachgewiesen 13.1999 -"],"title":[{"title_sort":"Clinical transplantation","title":"Clinical transplantation"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"doi":["10.1111/(ISSN)1399-0012"],"eki":["320439925"],"zdb":["2004801-4"],"issn":["1399-0012"]},"origin":[{"publisherPlace":"Oxford [u.] ; Copenhagen ; Oxford ; Oxford [u.a.]","dateIssuedDisp":"1999-","publisher":"Wiley-Blackwell ; Munksgaard International Publ. ; Blackwell Munksgaard ; Blackwell","dateIssuedKey":"1999"}]}],"name":{"displayForm":["Martina Sterneck, Gernot M. Kaiser, Nils Heyne, Nicolas Richter, Falk Rauchfuss, Andreas Pascher, Peter Schemmer, Lutz Fischer, Christian G. Klein, Silvio Nadalin, Frank Lehner, Utz Settmacher, Daniel Gotthardt, Martin Loss, Stephan Ladenburger, Peter Wimmer, Markus Dworak and Hans J. Schlitt"]},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"2016 May 10"}],"id":{"doi":["10.1111/ctr.12744"],"eki":["1588287742"]}} 
SRT |a STERNECKMALONGTERMFO2016